ΠΠΎΠΌΠΏΠ΅Π½ΡΠ°ΡΠΎΡΠ½ΡΠ΅ ΠΏΡΠΎΡΠ΅ΡΡΡ Π² ΠΌΠΎΠ·Π³Ρ ΠΌΡΡΠ΅ΠΉ ΠΏΡΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π΄Π΅Π³ΡΠ°Π΄Π°ΡΠΈΠΈ Π½ΠΈΠ³ΡΠΎΡΡΡΠΈΠ°ΡΠ½ΠΎΠΉ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΠΈ Π½ΠΎΠ²ΡΠΉ ΠΏΠΎΠ΄Ρ ΠΎΠ΄ ΠΊ ΠΈΡ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ
Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΡ Π½Π° ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΌΠΎΠ΄Π΅Π»ΠΈ Π΄ΠΎΡΠΈΠΌΠΏΡΠΎΠΌΠ½ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠΈ ΠΠ ΡΡΠΏΠ΅ΡΠ½ΠΎ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΠΏΡΠΈΠ½ΡΠΈΠΏΠΈΠ°Π»ΡΠ½ΠΎ Π½ΠΎΠ²Π°Ρ, Π»Π΅Π³ΠΊΠΎ Π²ΠΎΡΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΠΌΠ°Ρ ΠΈ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ½Π°Ρ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΡΠΊΡΡΡΠΎΠΉ ΡΠΎΡΠΌΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ — ΡΠ°ΠΊ Π½Π°Π·ΡΠ²Π°Π΅ΠΌΡΠΉ «ΠΏΡΠΎΠ²ΠΎΠΊΠ°ΡΠΈΠΎΠ½Π½ΡΠΉ ΡΠ΅ΡΡ», ΠΎΡΠ½ΠΎΠ²Π°Π½Π½ΡΠΉ Π½Π° ΠΊΡΠ°ΡΠΊΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΌ ΡΠ°ΡΡΠΈΡΠ½ΠΎΠΌ Π²ΡΠΊΠ»ΡΡΠ΅Π½ΠΈΠΈ ΡΠΈΠ½ΡΠ΅Π·Π° ΠΠ Π² ΠΠ-Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π½Π΅ΠΉΡΠΎΠ½Π°Ρ Π½ΠΈΠ³ΡΠΎΡΡΡΠΈΠ°ΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΠΏΡΡΠ΅ΠΌ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΎΠ±ΡΠ°ΡΠΈΠΌΠΎΠ³ΠΎ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ° Π’ΠΠΊΠ»ΡΡΠ΅Π²ΠΎΠ³ΠΎ… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- Π‘ΠΠΠ‘ΠΠ Π‘ΠΠΠ ΠΠ©ΠΠΠΠ
- ΠΠΠΠΠ I. ΠΠΠΠΠ ΠΠΠ’ΠΠ ΠΠ’Π£Π Π«
- 1. 1. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΠΌΠΎΠ·Π³Π°
- 1. 1. 1. ΠΡΡΠΏΠΏΡ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π½Π΅ΠΉΡΠΎΠ½ΠΎΠ² ΠΌΠΎΠ·Π³Π°
- 1. 1. 2. ΠΠΎΡΠ°ΠΌΠΈΠ½Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ Π½ΠΈΠ³ΡΠΎΡΡΡΠΈΠ°ΡΠ½Π°Ρ ΡΠΈΡΡΠ΅ΠΌΠ°
- 1. 2. Π€ΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠΈ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π½Π΅ΠΉΡΠΎΠ½ΠΎΠ² Π½ΠΈΠ³ΡΠΎΡΡΡΠΈΠ°ΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ
- 1. 2. 1. Π‘ΠΈΠ½ΡΠ΅Π· Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π°
- 1. 2. 2. ΠΠ°ΠΏΠ°ΡΠ°Π½ΠΈΠ΅ ΠΈ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π°
- 1. 2. 3. ΠΠΎΡΠ°ΠΌΠΈΠ½ΠΎΠ²ΡΠ΅ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΡ
- 1. 2. 4. ΠΠ±ΡΠ°ΡΠ½ΡΠΉ Π·Π°Ρ Π²Π°Ρ ΠΈ Π΄Π΅Π³ΡΠ°Π΄Π°ΡΠΈΡ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π°
- 1. 3. Π Π΅Π³ΡΠ»ΡΡΠΈΡ Π½ΠΈΠ³ΡΠΎΡΡΡΠΈΠ°ΡΠ½ΠΎΠΉ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ
- 1. 3. 1. ΠΡΡΠΎΡΠ΅Π³ΡΠ»ΡΡΠΈΡ
- 1. 3. 2. ΠΡΡΠ΅ΡΠ΅Π½ΡΠ½Π°Ρ ΡΠ΅Π³ΡΠ»ΡΡΠΈΡ
- 1. 4. Π€ΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π½ΠΈΠ³ΡΠΎΡΡΡΠΈΠ°ΡΠ½ΠΎΠΉ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ
- 1. 5. ΠΠΎΡΡΠΎ-ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ Π½ΠΈΠ³ΡΠΎΡΡΡΠΈΠ°ΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΠΏΡΠΈ Π½Π΅ΠΉΡΠΎΠ΄Π΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΠ²Π½ΡΡ
ΠΏΡΠΎΡΠ΅ΡΡΠ°Ρ
Π² ΠΌΠΎΠ·Π³Ρ
- 1. 5. 1. ΠΠ°ΡΠΊΠΈΠ½ΡΠΎΠ½ΠΈΠ·ΠΌ Ρ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°
- 1. 5. 2. ΠΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΠ΅ ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠ°ΡΠΊΠΈΠ½ΡΠΎΠ½ΠΈΠ·ΠΌΠ°
- 1. 6. ΠΠΎΠΌΠΏΠ΅Π½ΡΠ°ΡΠΎΡΠ½ΡΠ΅ ΠΏΡΠΎΡΠ΅ΡΡΡ Π² ΠΌΠΎΠ·Π³Ρ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΈ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ ΠΏΡΠΈ ΠΏΠ°ΡΠΊΠΈΠ½ΡΠΎΠ½ΠΈΠ·ΠΌΠ΅
- 1. 1. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΠΌΠΎΠ·Π³Π°
- ΠΠΠΠΠ II. ΠΠΠ’ΠΠ ΠΠΠΠ« Π ΠΠΠ’ΠΠΠ«
- II. 1. ΠΠΈΠ²ΠΎΡΠ½ΡΠ΅
- Π. 2. ΠΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΠ²Π΅Π΄Π΅Π½ΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΌΡΡΠ΅ΠΉ ΠΈ ΡΠ°Π·Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΈΡ Π½Π° Π³ΡΡΠΏΠΏΡ
- Π.Π. ΠΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΡ
- 11. 3. 1. ΠΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π΄ΠΎΡΠΈΠΌΠΏΡΠΎΠΌΠ½ΠΎΠΉ ΠΈ ΡΠΈΠΌΠΏΡΠΎΠΌΠ½ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠΉ ΠΏΠ°ΡΠΊΠΈΠ½ΡΠΎΠ½ΠΈΠ·ΠΌΠ° Ρ ΠΌΡΡΠ΅ΠΉ
- 11. 3. 2. ΠΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π°Π»ΡΡΠ°-ΠΌΠ΅ΡΠΈΠ»-ΠΏΠ°ΡΠ°-ΡΠΈΡΠΎΠ·ΠΈΠ½Π°
- 11. 4. ΠΠ·ΡΡΠΈΠ΅ ΠΈ ΠΎΠ±ΡΠ°Π±ΠΎΡΠΊΠ° ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π°
- 11. 4. 1. ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΠ΅ΡΠ½ΠΎΠΉ ΡΡΠ±ΡΡΠ°Π½ΡΠΈΠΈ ΠΈ ΡΡΡΠΈΠ°ΡΡΠΌΠ°
- 11. 4. 2. ΠΡΠ΅Π½ΠΊΠ° Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΈΡΠΎΠ·ΠΈΠ½Π³ΠΈΠ΄ΡΠΎΠΊΡΠΈΠ»Π°Π·Ρ
- 11. 4. 3. ΠΡΠ΅Π½ΠΊΠ° ΡΠΊΠΎΡΠΎΡΡΠΈ ΡΠΈΠ½ΡΠ΅Π·Π° Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π°
- 11. 4. 4. ΠΡΠ΅Π½ΠΊΠ° ΡΠΊΠΎΡΠΎΡΡΠΈ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΡ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π°
- 11. 4. 5. ΠΡΠ΅Π½ΠΊΠ° ΡΠΊΠΎΡΠΎΡΡΠΈ ΠΎΠ±ΡΠ°ΡΠ½ΠΎΠ³ΠΎ Π·Π°Ρ Π²Π°ΡΠ° Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π°
- 11. 5. ΠΡΡΠΎΠΊΠΎΡΡΡΠ΅ΠΊΡΠΈΠ²Π½Π°Ρ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠ½Π°Ρ Ρ ΡΠΎΠΌΠ°ΡΠΎΠ³ΡΠ°ΡΠΈΡ Ρ ΡΠ»Π΅ΠΊΡΡΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π΄Π΅ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ
- 11. 6. ΠΠΈΠ΄ΠΊΠΎΡΡΠ½Π°Ρ ΡΡΠΈΠ½ΡΠΈΠ»Π»ΡΡΠΈΠΎΠ½Π½Π°Ρ ΡΠΏΠ΅ΠΊΡΡΠΎΠΌΠ΅ΡΡΠΈΡ
- 11. 7. Π‘ΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΠ±ΡΠ°Π±ΠΎΡΠΊΠ° ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ²
- ΠΠΠΠΠ III. Π ΠΠΠ£ΠΠ¬Π’ΠΠ’Π«
- III. 1. «ΠΠΎΠ΄Π΅Π»ΠΈ Π΄ΠΎΡΠΈΠΌΠΏΡΠΎΠΌΠ½ΠΎΠΉ ΠΈ ΡΠ°Π½Π½Π΅ΠΉ ΡΠΈΠΌΠΏΡΠΎΠΌΠ½ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠΉ ΠΏΠ°ΡΠΊΠΈΠ½ΡΠΎΠ½ΠΈΠ·ΠΌΠ° Ρ ΠΌΡΡΠ΅ΠΉ»
- III. 1.1. ΠΠΈΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π° ΠΈ Π΅Π³ΠΎ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠΎΠ² Π² ΡΠ΅ΡΠ½ΠΎΠΉ ΡΡΠ±ΡΡΠ°Π½ΡΠΈΠΈ ΠΈ Π² ΡΡΡΠΈΠ°ΡΡΠΌΠ΅
- III. 1.2. ΠΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠΈΡΠΎΠ·ΠΈΠ½Π³ΠΈΠ΄ΡΠΎΠΊΡΠΈΠ»Π°Π·Ρ
- III. 1.3. Π‘ΠΈΠ½ΡΠ΅Π· Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π°
- III. 1.4. ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π°
- III. 1.5. ΠΠ±ΡΠ°ΡΠ½ΡΠΉ Π·Π°Ρ
Π²Π°Ρ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π°
- III. 2. «ΠΡΠΎΠ²ΠΎΠΊΠ°ΡΠΈΠΎΠ½Π½ΡΠΉ ΡΠ΅ΡΡ»
- 111. 2. 1. ΠΠΎΠ΄Π±ΠΎΡ Π΄ΠΎΠ·Ρ Π°Π»ΡΡΠ°-ΠΌΠ΅ΡΠΈΠ»-ΠΏΠ°ΡΠ°-ΡΠΈΡΠΎΠ·ΠΈΠ½Π° Π½Π° ΠΈΠ½ΡΠ°ΠΊΡΠ½ΡΡ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ Π΄Π»Ρ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ «ΠΏΡΠΎΠ²ΠΎΠΊΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΡΠ°»
- 111. 2. 2. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ «ΠΏΡΠΎΠ²ΠΎΠΊΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΡΠ°» Π½Π° ΠΌΠΎΠ΄Π΅Π»ΠΈ Π΄ΠΎΡΠΈΠΌΠΏΡΠΎΠΌΠ½ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠΈ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΠ°ΡΠΊΠΈΠ½ΡΠΎΠ½Π°
- III. 2. «ΠΡΠΎΠ²ΠΎΠΊΠ°ΡΠΈΠΎΠ½Π½ΡΠΉ ΡΠ΅ΡΡ»
- VI. 1. Π€ΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½Π°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π½ΠΈΠ³ΡΠΎΡΡΡΠΈΠ°ΡΠ½ΠΎΠΉ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ Π½Π° ΠΌΠΎΠ΄Π΅Π»ΡΡ Π΄ΠΎΡΠΈΠΌΠΏΡΠΎΠΌΠ½ΠΎΠΉ ΠΈ ΡΠΈΠΌΠΏΡΠΎΠΌΠ½ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠΉ ΠΏΠ°ΡΠΊΠΈΠ½ΡΠΎΠ½ΠΈΠ·ΠΌΠ° Ρ ΠΌΡΡΠ΅ΠΉ
- VI. 1.2. ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π°
- VI. 1.3. ΠΠ±ΡΠ°ΡΠ½ΡΠΉ Π·Π°Ρ Π²Π°Ρ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π°
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠ½Π΄ΡΠ΅Π΅Π²Π° Π. Π. Π‘ΡΡΡΠΊΡΡΡΠ½ΠΎ-ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½Π°Ρ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ Π½Π΅ΡΠ²Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ. Π‘ΠΠ±.: ΠΠ·Π΄Π°ΡΠ΅Π»ΡΡΡΠ²ΠΎ Π‘ΠΠ±Π£, 2005. 246 Ρ.
- ΠΡΡΡΠ°Π½ΡΠ½ Π. Π., ΠΡΠ΅Π»Π»ΠΈΠ½ Π. Π. Π₯Π²ΠΎΡΡΠ°ΡΠΎΠ΅ ΡΠ΄ΡΠΎ: ΠΡΠ΅ΡΠΊΠΈ ΠΏΠΎ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΠΈ, ΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ. Π.: ΠΠ°ΡΠΊΠ°, 1976. 223 Ρ.
- ΠΠΎΠ»ΡΠ±Π΅Π² Π. Π., ΠΠ΅Π²ΠΈΠ½ Π―. Π., ΠΠ΅ΠΉΠ½ Π. Π. ΠΠΎΠ»Π΅Π·Π½Ρ ΠΠ°ΡΠΊΠΈΠ½ΡΠΎΠ½Π° ΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌ ΠΏΠ°ΡΠΊΠΈΠ½ΡΠΎΠ½ΠΈΠ·ΠΌΠ°. Π: ΠΠΠΠΏΡΠ΅ΡΡ, 1999. 387 Ρ.
- ΠΡΡΠΆΠ°Π½ΠΎΠ²ΡΠΊΠΈΠΉ Π. Π., ΠΡΡΠΏΠΈΠ½Π° Π. Π. ΠΠ΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½ΠΈΠ³ΡΠΎΡΡΡΠΈΠ°ΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΠΊΠ°ΠΊ Π΄ΠΈΠ·ΡΠ΅Π³ΡΠ»ΡΡΠΈΠΎΠ½Π½ΡΠΉ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π·Π°Π²ΠΈΡΠΈΠΌΠΎΠ³ΠΎ Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ°. ΠΡΡΠ½Π°Π» Π½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΏΡΠΈΡ ΠΈΠ°ΡΡΠΈΠΈ ΠΈΠΌ. Π‘. Π‘. ΠΠΎΡΡΠ°ΠΊΠΎΠ²Π°. 2003. — Π’. 4. — Π‘. 42−47.
- ΠΡΡΠΆΠ°Π½ΠΎΠ²ΡΠΊΠΈΠΉ Π. Π., ΠΠ°ΡΠ°Π±Π°Π½Ρ Π. Π., ΠΠ°Π³Π°Π΅Π²Π° Π‘. Π., ΠΡΡΠ΅ΡΡΠ½Ρ Π. Π. ΠΈ ΠΠ°ΡΠ°Π±Π°Π½Ρ Π. Π. ΠΠΎΠ»Π΅Π·Π½Ρ ΠΠ°ΡΠΊΠΈΠ½ΡΠΎΠ½Π° (ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΡ, ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·, ΠΊΠ»ΠΈΠ½ΠΈΠΊΠ°, Π»Π΅ΡΠ΅Π½ΠΈΠ΅, ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ°). Π.: ΠΠ΅Π΄ΠΈΡΠΈΠ½Π°, 2002. 336 Ρ.
- ΠΠΈΡΠ²ΠΈΠ½Π΅Π½ΠΊΠΎ Π. Π. ΠΠΎΠ»Π΅Π·Π½Ρ ΠΠ°ΡΠΊΠΈΠ½ΡΠΎΠ½Π°. Π.: ΠΠΈΠΊΠ»ΠΎΡ, 2006. 216 Ρ.
- ΠΠΈΡΠ²ΠΈΠ½Π΅Π½ΠΊΠΎ Π. Π., ΠΠ΄ΠΈΠ½Π°ΠΊ Π. Π. ΠΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠ½ΠΎΠ²Ρ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΡ ΠΈ ΠΏΡΠΈΡ ΠΎΡΠΈΡΠ΅ΡΠΊΠΈΡ Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ ΠΏΡΠΈ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΠ°ΡΠΊΠΈΠ½ΡΠΎΠ½Π°. ΠΡΡΠ½Π°Π» Π½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΏΡΠΈΡ ΠΈΠ°ΡΡΠΈΠΈ ΠΈΠΌ. Π‘. Π‘. ΠΠΎΡΡΠ°ΠΊΠΎΠ²Π°. 2004. — Π’. 4. — Π‘. 76−81.
- ΠΡΠ΅Π»Π»ΠΈΠ½ Π. Π., ΠΡΡΡΠ°Π½ΡΠ½ Π. Π. ΠΠΈΠ³ΡΠΎΡΡΡΠΈΠΎΠ½ΠΈΠ³ΡΠ°Π»ΡΠ½Π°Ρ ΡΠΈΡΡΠ΅ΠΌΠ°. Π: ΠΠ΅Π΄ΠΈΡΠΈΠ½Π°, 1989. 271 Ρ.
- Π‘ΡΠ²ΠΎΡΠΎΠ² Π. Π€. Π‘ΡΡΠΈΠ°ΡΠ½Π°Ρ ΡΠΈΡΡΠ΅ΠΌΠ° ΠΈ ΠΏΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π.: ΠΠ°ΡΠΊΠ°, 1980. 280 Ρ.
- Π¨ΡΠ²Π°Π΅Π² Π., Π‘ΡΠ²ΠΎΡΠΎΠ² Π. ΠΠ°Π·Π°Π»ΡΠ½ΡΠ΅ Π³Π°Π½Π³Π»ΠΈΠΈ ΠΈ ΠΏΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π‘ΠΠ±.: ΠΠ°ΡΠΊΠ°, 2001.278 Ρ.
- Abercrombie Π. D., Bonatz Π. Π. and Zigmond Π. J. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res. 1990. — V. 525. — P. 36−44.
- Agid Y., Javoy F. and Glowinski J. Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nat New Biol. 1973. — V. 245. — P. 150−151.
- Allen N. J. and Barres B. A. Signaling between glia and neurons: focus on synaptic plasticity. Curr Opin Neurobiol. 2005. — V. 15. — P. 542−548.
- Allert N., Barbe M. T., Timmermann L. and Coenen V. A. Long-term care of Parkinson patients with deep brain stimulation. Fortschr Neurol Psychiatr. -2011.-V. 79.-P. 696−702.
- Anden N. E., Strombom U. and Svensson T. H. Dopamine and noradrenaline receptor stimulation: reversal of reserpine-induced suppression of motor activity. Psychopharmacologia. 1973. — V. 29. — P. 289−298.
- Ariano M. A. Striatal D1 dopamine receptor distribution following chemical lesion of the nigrostriatal pathway. Brain Res. 1988. — V. 443. — P. 204−214.
- Au W. L., Adams J. R., Troiano A. R. and Stoessl A. J. Parkinson’s disease: in vivo assessment of disease progression using positron emission tomography. Brain Res Mol Brain Res. 2005. — V. 134. — P. 24−33.
- Benabid A. L. Stimulation therapies for Parkinson’s disease: over the past two decades. Bull Acad Natl Med. 2010. — V. 194. — P. 1273−1286.
- Bergson C., Mrzljak L., Smiley J. F., Pappy M., Levenson R. and Goldman-Rakic P. S. Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain. J Neurosci. 1995. — V. 15. -P. 7821−7836.
- Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K. and Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973. — Y. 20. -P. 415−455.
- Besson M. J., Cheramy A., Feltz P. and Glowinski J. Release of newly synthesized dopamine from dopamine-containing terminals in the striatum of the rat. Proc Natl Acad Sci USA.- 1969. V. 62. — P. 741−748.
- Bezard E. and Gross C. E. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog Neurobiol. 1998. -V. 55.-P. 93−116.
- Bezard E., Gross C. E. and Brotchie J. M. Presymptomatic compensation in Parkinson’s disease is not dopamine-mediated. Trends Neurosci. 2003. — V. 26. -P. 215−221.
- Bezard E., Imbert C., Deloire X., Bioulac B. and Gross C. E. A chronic MPTP model reproducing the slow evolution of Parkinson’s disease: evolution of motor symptoms in the monkey. Brain Res. 1997. — V. 766. — P. 107−112.
- Bjorklund A. and Nobin A. Fluorescence histochemical and microspectrofluorometric mapping of dopamine and noradrenaline cell groups in the rat diencephalon. Brain Res. 1973. — V. 51. — P. 193−205.
- Bunney B. S., Walters J. R., Roth R. H. and Aghajanian G. K. Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther. 1973. — V. 185. — P. 560−571.
- Buonamici M., Caccia C., Carpentieri M., Pegrassi L., Rossi A. C. and Di Chiara G. D-l receptor supersensitivity in the rat striatum after unilateral 6-hydroxydopamine lesions. Eur J Pharmacol. 1986. — V. 126. — P. 347−348.
- Carlsson A. Treatment of Parkinson’s with L-DOPA. The early discovery phase, and a comment on current problems. J Neural Transm. 2002. — V. 109. -P. 777−787.
- Carlsson A. and Lindqvist M. In-vivo measurements of tryptophan and tyrosine hydroxylase activities in mouse brain. J Neural Transm. 1973. — V. 34. — P. 7991.
- Carlsson, A., Rosengren, E., Bertler, A., Nilsson, J., 1957. Effect of reserpine on the metabolism of catechol amines. In: Garattini, S., Ghetti, C. (Eds.), Psychotropic Drugs. Elsevier, Amsterdam, pp. 363−372.
- Cash R., Raisman R., Ploska A. and Agid Y. Dopamine D-l receptor and cyclic AMP-dependent phosphorylation in Parkinson’s disease. J Neurochem. 1987. -V. 49.-P. 1075−1083.
- Cass W. A. and Gerhardt G. A. Direct in vivo evidence that D2 dopamine receptors can modulate dopamine uptake. Neurosci Lett. 1994. — V. 176. — P. 259−263.
- Chevalier G. and Deniau J. M. Disinhibition as a basic process in the expression of striatal functions. Trends Neurosci. 1990. — V. 13. — P. 277−280.
- Christenson J. G., Dairman W. and Udenfriend S. Preparation and properties of a homogeneous aromatic L-amino acid decarboxylase from hog kidney. Arch Biochem Biophys. 1970. — V. 141. — P. 356−367.
- Corrodi H. and Hanson L. C. Central effects of an inhibitor of tyrosine hydroxylation. Psychopharmacologia. 1966. — V. 10. — P. 116−125.
- Cragg S. J. and Greenfield S. A. Differential autoreceptor control of somatodendritic and axon terminal dopamine release in substantia nigra, ventral tegmental area, and striatum. J Neurosci. 1997. — V. 17. — P. 5738−5746.
- Creese I., Burt D. R. and Snyder S. H. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science. 1977. — V. 197.-P. 596−598.
- Creese I. and Snyder S. H. Nigrostriatal lesions enhance striatal 3H-apomorphine and 3H-spiroperidol binding. Eur J Pharmacol. 1979. — V. 56. -P. 277−281.
- Dearry A., Gingrich J. A., Falardeau P., Fremeau R. T., Jr., Bates M. D. and Caron M. G. Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature. 1990. — V. 347. — P. 72−76.
- DeKosky S. T. and Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science. 2003. — V. 302. — P. 830 834.
- DeLong M. R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990. — V. 13. — P. 281−285.
- Diaz J., Pilon C., Le Foil B., Gros C., Triller A., Schwartz J. C. and Sokoloff P. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci. 2000. — V. 20. — P. 8677−8684.
- Dominic J. A. and Moore K. E. Acute effects of alpha-methyltyrosine on brain catecholamine levels and on spontaneous and amphetamine-stimulated motor activity in mice. Arch Int Pharmacodyn Ther. 1969. — V. 178. — P. 166−176.
- Dravid A., Jaton A. L., Enz A. and Frei P. Spontaneous recovery from motor asymmetry in adult rats with 6-hydroxydopamine-induced partial lesions of the substantia nigra. Brain Res. 1984. — V. 311. — P. 361−365.
- Eberling J. L., Bankiewicz K. S., Pivirotto P., Bringas J., Chen K., Nowotnik D. P., Steiner J. P., Budinger T. F. and Jagust W. J. Dopamine transporter loss and clinical changes in MPTP-lesioned primates. Brain Res. 1999. — V. 832. — P. 184−187.
- Ehringer H. and Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr. 1960. — V. 38. — P. 1236−1239.
- Elsworth J. D. and Roth R. H. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson’s disease. Exp Neurol. 1997. — V. 144. — P. 4−9.
- Engelman K., Horwitz D., Jequier E. and Sjoerdsma A. Biochemical and pharmacologic effects of alpha-methyltyrosine in man. J Clin Invest. 1968a. -V. 47. — P. 577−594.
- Engelman K., Jequier E., Udenfriend S. and Sjoerdsma A. Metabolism of alpha-methyltyrosine in man: relationship to its potency as an inhibitor of catecholamine biosynthesis. J Clin Invest. 1968b. — V. 47. — P. 568−576.
- Ennis C., Kemp J. D. and Cox B. Characterisation of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in the striatum. J Neurochem. 1981. — V. 36. — P. 1515−1520.
- Fagervall I. and Ross S. B. A and B forms of monoamine oxidase within the monoaminergic neurons of the rat brain. J Neurochem. 1986. — V. 47. — P. 569 576.
- Falkenburger B. H., Barstow K. L. and Mintz I. M. Dendrodendritic inhibition through reversal of dopamine transport. Science. 2001. — V. 293. — P. 24 652 470.
- Farnebo L. O. and Hamberger B. Drug-induced changes in the release of 3 H-monoamines from field stimulated rat brain slices. Acta Physiol Scand Suppl. -1971.-V. 371.-P. 35−44.
- Fink J. S. and Smith G. P. Mesolimbicocortical dopamine terminal fields are necessary for normal locomotor and investigatory exploration in rats. Brain Res. 1980. — V. 199. — P. 359−384.
- Fluxe K., Hokfelt T., Johansson O., Jonsson G., Lidbrink P. and Ljungdahl A. The origin of the dopamine nerve terminals in limbic and frontal cortex. Evidence for meso-cortico dopamine neurons. Brain Res. 1974. — V. 82. — P. 349−355.
- Fox M. W., Ahlskog J. E. and Kelly P. J. Stereotactic ventrolateralis thalamotomy for medically refractory tremor in post-levodopa era Parkinson’s disease patients. J Neurosurg. 1991. — V. 75. — P. 723−730.
- Freyaldenhoven T. E., Cadet J. L. and Ali S. F. The dopamine-depleting effects of l-methyl-4-phenyl-l, 2,3,6-tetrahydropyridine in CD-I mice are gender-dependent. Brain Res. 1996. — V. 735. — P. 232−238.
- Fried R. C. and Blaustein M. P. Retrieval and recycling of synaptic vesicle membrane in pinched-off nerve terminals (synaptosomes). J Cell Biol. 1978. -V. 78.-P. 685−700.
- Gerfen C. R., Engber T. M., Mahan L. C., Susel Z., Chase T. N., Monsma F. J., Jr. and Sibley D. R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990. — V. 250. — P. 14 291 432.
- Gerlach M. and Riederer P. Animal models of Parkinson’s disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm. -1996.-V. 103.-P. 987−1041.
- Girault J. A., Raisman-Vozari R., Agid Y. and Greengard P. Striatal phosphoproteins in Parkinson disease and progressive supranuclear palsy. Proc Natl Acad Sci USA.- 1989. Y. 86. — P. 2493−2497.
- Glitsch M. D. Spontaneous neurotransmitter release and Ca2+ How spontaneous is spontaneous neurotransmitter release? Cell Calcium. — 2008. — V. 43.-P. 9−15.
- Grace A. A. and Bunney B. S. The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci. 1984a. — V. 4. — P. 2877−2890.
- Grace A. A. and Bunney B. S. The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci. 1984b. — V. 4. — P. 2866−2876.
- Graybiel A. M. The basal ganglia. Trends Neurosci. 1995. — V. 18. — P. 60−62.
- Green A. L., Bittar R. G., Bain P., Scott R. B., Joint C., Gregory R. and Aziz T. Z. STN vs. Pallidal Stimulation in Parkinson Disease: Improvement With Experience and Better Patient Selection. Neuromodulation. 2006. — V. 9. — P. 21−27.
- Greenamyre J. T., Sherer T. B., Betarbet R. and Panov A. V. Complex I and Parkinson’s disease. IUBMB Life. 2001. — V. 52. — P. 135−141.
- Grimsby J., Chen K., Wang L. J., Lan N. C. and Shih J. C. Human monoamine oxidase A and B genes exhibit identical exon-intron organization. Proc Natl Acad Sci USA.- 1991. V. 88. — P. 3637−3641.
- Hanson L. C. The disruption of conditioned avoidance response following selective depletion of brain catechol amines. Psychopharmacologia. 1965. — V. 8. — P. 100−110.
- Hatori K., Kondo T. and Mizuno Y. Levodopa loading test as an early marker of Parkinson’s disease. Nihon Rinsho. 1997. — V. 55. — P. 207−212.
- Haycock J. W. Species differences in the expression of multiple tyrosine hydroxylase protein isoforms. J Neurochem. 2002. — V. 81. — P. 947−953.
- Hefti F., Melamed E. and Wurtman R. J. The site of dopamine formation in rat striatum after L-dopa administration. J Pharmacol Exp Ther. 1981. — V. 217. -P. 189−197.
- Heimer L., Switzer R. D. and Van Hoesen G. W. Ventral striatum and ventral pallidum: Components of the motor system? Trends Neurosci. 1982. — V. 5. -P. 83−87.
- Henn F. A. and Hamberger A. Glial cell function: uptake of transmitter substances. Proc Natl Acad Sci U S A. 1971. — V. 68. — P. 2686−2690.
- Hoffman A. F. and Gerhardt G. A. In vivo electrochemical studies of dopamine clearance in the rat substantia nigra: effects of locally applied uptake inhibitorsand unilateral 6-hydroxydopamine lesions. J Neurochem. 1998. — V. 70. — P. 179−189.
- Hoffman A. F., Lupica C. R. and Gerhardt G. A. Dopamine transporter activity in the substantia nigra and striatum assessed by high-speed chronoamperometric recordings in brain slices. J Pharmacol Exp Ther. 1998. -V. 287. — P. 487−496.
- Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev. 1966. — V. 18. — P. 925−964.
- Hornykiewicz O. Neurochemical pathology and the etiology of Parkinson’s disease: basic facts and hypothetical possibilities. Mt Sinai J Med. 1988. — V. 55.-P. 11−20.
- Hosli E. and Hosli L. Autoradiographic studies on the uptake of 3H-dopamine by neurons and astrocytes in explant and primary cultures of rat CNS: effects of uptake inhibitors. Int J Dev Neurosci. 1997. — V. 15. — P. 45−53.
- Hughes A. J., Ben-Shlomo Y., Daniel S. E. and Lees A. J. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology. 1992. — V. 42. — P. 1142−1146.
- Hutchins D. A. and Rogers K. J. Effect of depletion of cerebral monoamines on the concentration of glycogen and on amphetamine-induced glycogenolysis in the brain. Br J Pharmacol. 1973. — V. 48. — P. 19−29.
- Inazu M., Takeda H. and Matsumiya T. The role of glial monoamine transporters in the central nervous system. Nihon Shinkei Seishin Yakurigaku Zasshi. 2003. — V. 23. — P. 171−178.
- Jackson-Lewis V., Jakowec M., Burke R. E. and Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-l, 2,3,6-tetrahydropyridine. Neurodegeneration. 1995. — V. 4.- P. 257−269.
- Jankovic J. International Classification of Diseases, tenth revision: neurological adaptation (ICD-10 NA): extrapyramidal and movement disorders. Mov Disord.- 1995. -V. 10. P. 533−540.
- Jankovic J., Schwartz K. and Vander Linden C. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord. 1989. — V. 4. — P. 303−309.
- Jeffery D. R. and Roth J. A. Characterization of membrane-bound and soluble catechol-O-methyltransferase from human frontal cortex. J Neurochem. 1984.- V. 42. P. 826−832.
- Johnston J. P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol. 1968. — V. 17. — P. 1285−1297.
- Jones S. R., Gainetdinov R. R., Wightman R. M. and Caron M. G. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci. 1998. — V. 18. — P. 1979−1986.
- Joyce J. N. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson’s disease cases. Brain Res. 1993. — V. 600. — P. 156−160.
- Kastner A., Hirsch E. C., Agid Y. and Javoy-Agid F. Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson’s disease. Brain Res. 1993a. — V. 606. — P. 341−345.
- Kehr W., Carlsson A., Lindqvist M., Magnusson T. and Atack C. Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity. J Pharm Pharmacol. 1972. — V. 24. — P. 744−747.
- Kelly R. B. Storage and release of neurotransmitters. Cell. 1993. — V. 72 Suppl. — P. 43−53.
- Kirchhoff J., Mork A., Brennum L. T. and Sager T. N. Striatal extracellular dopamine levels and behavioural reversal in MPTP-lesioned mice. Neuroreport. 2009. — V. 20. — P. 482−486.
- Kitai S. T. and Deniau J. M. Cortical inputs to the subthalamus: intracellular analysis. Brain Res. 1981. — V. 214. — P. 411−415.
- Kristensen H. K., Lau Y. Y. and Ewing A. G. Capillary electrophoresis of single cells: observation of two compartments of neurotransmitter vesicles. J Neurosci Methods. 1994. — V. 51. — P. 183−188.
- Kumer S. C. and Vrana K. E. Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem. 1996. — V. 67. — P. 443−462.
- Lang A. E. and Marsden C. D. Alpha methylparatyrosine and tetrabenazine in movement disorders. Clin Neuropharmacol. 1982. — V. 5. — P. 375−387.
- Langston J. W., Ballard P., Tetrad J. W. and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983. — V. 219.-P. 979−980.
- Lee J. M., McLean S., Maggio J. E., Zamir N., Roth R. H., Eskay R. L. and Bannon M. J. The localization and characterization of substance P and substance K in striatonigral neurons. Brain Res. 1986. — Y. 371. — P. 152−154.
- Lee T., Seeman P., Rajput A., Farley I. J. and Hornykiewicz O. Receptor basis for dopaminergic supersensitivity in Parkinson’s disease. Nature. 1978. — V. 273.-P. 59−61.
- Levitt M., Spector S., Sjoerdsma A. and Udenfriend S. Elucidation of the Rate-Limiting Step in Norepinephrine Biosynthesis in the Perfused Guinea-Pig Heart. J Pharmacol Exp Ther. 1965. — V. 148. — P. 1−8.
- Lewis D. A., Melchitzky D. S. and Haycock J. W. Four isoforms of tyrosine hydroxylase are expressed in human brain. Neuroscience. 1993. — V. 54. — P. 477−492.
- Lewis D. A., Melchitzky D. S. and Haycock J. W. Expression and distribution of two isoforms of tyrosine hydroxylase in macaque monkey brain. Brain Res. -1994.-V. 656.-P. 1−13.
- Lichtensteiger W., Hefti F., Felix D., Huwyler T., Melamed E. and Schlumpf M. Stimulation of nigrostriatal dopamine neurones by nicotine. Neuropharmacology. 1982. — V. 21. — P. 963−968.
- Lloyd K. G., Davidson L. and Hornykiewicz O. The neurochemistry of Parkinson’s disease: effect of L-dopa therapy. J Pharmacol Exp Ther. 1975. -V. 195. — P. 453−464.
- Lo Bianco C., Ridet J. L., Schneider B. L., Deglon N. and Aebischer P. alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease. Proc Natl Acad Sci USA.- 2002. V. 99. -P. 10 813−10 818.
- Lorenc-Koci E., Ossowska K., Wardas J. and Wolfarth S. Does reserpine induce parkinsonian rigidity? J Neural Transm Park Dis Dement Sect. 1995. -V. 9.-P. 211−223.
- Lundstrom K., Salminen M., Jalanko A., Savolainen R. and Ulmanen I. Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol. -1991. V. 10. — P. 181−189.
- Mannisto P. T. and Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 1999. — V. 51. — P. 593−628.
- Marshall J. F., Navarrete R. and Joyce J. N. Decreased striatal D1 binding density following mesotelencephalic 6-hydroxy dopamine injections: an autoradiographic analysis. Brain Res. 1989. — V. 493. — P. 247−257.
- Masserano J. M. and Weiner N. Tyrosine hydroxylase regulation in the central nervous system. Mol Cell Biochem. 1983. — V. 53−54. — P. 129−152.
- McCallum S. E., Parameswaran N., Perez X. A., Bao S., Mcintosh J. M., Grady S. R. and Quik M. Compensation in pre-synaptic dopaminergic function following nigrostriatal damage in primates. J Neurochem. 2006. — V. 96. — P. 960−972.
- McCann U. D., Penetar D. M. and Belenky G. Acute dystonic reaction in normal humans caused by catecholamine depletion. Clin Neuropharmacol. -1990. -V. 13. P. 565−568.
- Meador-Woodruff J. H., Mansour A., Bunzow J. R., Van Tol H. H., Watson S. J., Jr. and Civelli O. Distribution of D2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci USA.- 1989. V. 86. — P. 7625−7628.
- Meiergerd S. M., Patterson T. A. and Schenk J. O. D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J Neurochem. 1993. — V. 61. — P. 764−767.
- Mercer L., del Fiacco M. and Cuello A. C. The smooth endoplasmic reticulum as a possible storage site for dendritic dopamine in substantia nigra neurones. Experientia. 1979. — V. 35. — P. 101−103.
- Meredith G. E., Totterdell S., Petroske E., Santa Cruz K., Callison R. C., Jr. and Lau Y. S. Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson’s disease. Brain Res. 2002. — V. 956. -P. 156−165.
- Missale C., Nash S. R., Robinson S. W., Jaber M. and Caron M. G. Dopamine receptors: from structure to function. Physiol Rev. 1998. — V. 78. — P. 189−225.
- Miyamoto T., Bekku H., Moriyama E. and Tsuchida S. Present role of stereotactic thalamotomy for parkinsonism. Retrospective analysis of operative results and thalamic lesions in computed tomograms. Appl Neurophysiol. -1985.-V. 48.-P. 294−304.
- Monsma F. J., Jr., McVittie L. D., Gerfen C. R., Mahan L. C. and Sibley D. R. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature. 1989.-V. 342.-P. 926−929.
- Moore K. E. Effects of alpha-methyltyrosine on brain catecholamines and conditioned behavior in guinea pigs. Life Sci. 1966. — V. 5. — P. 55−65.
- Moore K. E. Behavioural effects of alpha-methyltyrosine administered in the diets of mice pretreated with a monoamine oxidase inhibitor. J Pharm Pharmacol. 1968. — V. 20. — P. 656−657.
- Moore K. E. and Dominic J. A. Tyrosine hydroxylase inhibitors. Fed Proc. -1971.-V. 30.-P. 859−870.
- Moore K. E. and Rech R. H. Antagonism by monoamine oxidase inhibitors of alpha-methyltyrosine-induced catecholamine depletion and behavioral depression. J Pharmacol Exp Ther. 1967. — V. 156. — P. 70−75.
- Moore K. E., Wright P. F. and Bert J. K. Toxicologic studies with alpha-methyltyrosine, an inhibitor of tyrosine hydroxylase. J Pharmacol Exp Ther. -1967.-V. 155.-P. 506−515.
- Moro E. and Lang A. E. Criteria for deep-brain stimulation in Parkinson’s disease: review and analysis. Expert Rev Neurother. 2006. — V. 6. — P. 16 951 705.
- Mulder A. H., van den Berg W. B. and Stoof J. C. Calcium-dependent release of radiolabeled catecholamines and serotonin from rat brain synaptosomes in a superfusion system. Brain Res. 1975. — V. 99. — P. 419−424.
- Nagatsu T. Genes for human catecholamine-synthesizing enzymes. Neurosci Res. 1991. -V. 12. — P. 315−345.
- Nagatsu T., Kato T., Numata Y., Ikuta K. and Sano M. Phenylethanolamine N-methyltransferase and other enzymes of catecholamine metabolism in human brain. Clin Chim Acta. 1977. — V. 75. — P. 221−232.
- Nicklas W. J., Youngster S. K., Kindt M. V. and Heikkila R. E. MPTP, MPP+ and mitochondrial function. Life Sci. 1987. — V. 40. — P. 721−729.
- Nirenberg M. J., Vaughan R. A., Uhl G. R., Kuhar M. J. and Pickel V. M. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci. 1996. — V. 16. — P. 436−447.
- Olanow C. W. A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson’s disease. Mov Disord. 1993. — V. 8 Suppl 1. — P. SI-7.
- Owen A. M., James M., Leigh P. N., Summers B. A., Marsden C. D., Quinn N. P., Lange K. W. and Robbins T. W. Fronto-striatal cognitive deficits at different stages of Parkinson’s disease. Brain. 1992. — V. 115 (Pt 6). — P. 1727−1751.
- Parker W. D., Jr., Boyson S. J. and Parks J. K. Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol. 1989. — V. 26. -P. 719−723.
- Perez X. A., Parameswaran N., Huang L. Z., O’Leary K. T. and Quik M. Presynaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates. J Neurochem. 2008. — V. 105. — P. 1861−1872.
- Petroske E., Meredith G. E., Callen S., Totterdell S. and Lau Y. S. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience. 2001. — V. 106. — P. 589−601.
- Pierot L., Desnos C., Blin J., Raisman R., Scherman D., Javoy-Agid F., Ruberg M. and Agid Y. D1 and D2-type dopamine receptors in patients with Parkinson’s disease and progressive supranuclear palsy. J Neurol Sci. 1988. -V. 86.-P. 291−306.
- Pifl C. and Hornykiewicz O. Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys. Neurochem Int. 2006. — V. 49.-P. 519−524.
- Plock N. and Kloft C. Microdialysis—theoretical background and recent implementation in applied life-sciences. Eur J Pharm Sci. 2005. — V. 25. — P. 124.
- Poewe W. Non-motor symptoms in Parkinson’s disease. Eur J Neurol. 2008. -V. 15 Suppl 1. — P. 14−20.
- Pothos E. N., Davila V. and Sulzer D. Presynaptic recording of quanta from midbrain dopamine neurons and modulation of the quantal size. J Neurosci. -1998.-V. 18.-P. 4106−4118.
- Prut L. and Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol. 2003. — V. 463. -P.3−33.
- Quinton M. S. and Yamamoto B. K. Causes and consequences of methamphetamine and MDMA toxicity. Aaps J. 2006. — V. 8. — P. 337−347.
- Raiteri M., Cerrito F., Cervoni A. M. and Levi G. Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J Pharmacol Exp Ther. 1979. — V. 208. — P. 195−202.
- Rech R. H., Borys H. K. and Moore K. E. Alterations in behavior and brain catecholamine levels in rats treated with alpha-methyltyrosine. J Pharmacol Exp Ther. 1966. — V. 153. — P. 412−419.
- Redmond D. E., Jr., Maas J. W., Kling A. and Dekirmenjian H. Changes in primate social behavior after treatment with alpha-methyl-para-tyrosine. Psychosom Med. 1971. — V. 33. — P. 97−113.
- Reith M. E., Xu C. and Chen N. H. Pharmacology and regulation of the neuronal dopamine transporter. Eur J Pharmacol. 1997. — V. 324. — P. 1−10.
- Riederer P. and Wuketich S. Time course of nigrostriatal degeneration in parkinson’s disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm. 1976. — V. 38. — P. 277−301.
- Rinne U. K., Lonnberg P. and Koskinen V. Dopamine receptors in the Parkinsonian brain. J Neural Transm. 1981. — V. 51. — P. 97−106.
- Roberts P. J., McBean G. J., Sharif N. A. and Thomas E. M. Striatal glutamatergic function: modifications following specific lesions. Brain Res. -1982.-V. 235.-P. 83−91.
- Rosegay H. An experimental investigation of the connections between the corpus striatum and substantia nigra in the cat. J Comp Neurol. 1944. — V. 80. -P. 293−321.
- Ross S. B. and Renyi A. L. Inhibition of the uptake of tritiated catecholamines by antidepressant and related agents. Eur J Pharmacol. 1967. — V. 2. — P. 181 186.
- Rothblat D. S. and Schneider J. S. Regional differences in striatal dopamine uptake and release associated with recovery from MPTP-induced parkinsonism: an in vivo electrochemical study. J Neurochem. 1999. — V. 72. — P. 724−733.
- Rudnick G. Bioenergetics of neurotransmitter transport. J Bioenerg Biomembr. 1998.-V. 30. -P. 173−185.
- Salah R. S., Kuhn D. M. and Galloway M. P. Dopamine autoreceptors modulate the phosphorylation of tyrosine hydroxylase in rat striatal slices. J Neurochem. -1989.-V. 52.-P. 1517−1522.
- Santiago M., Granero L., Machado A. and Cano J. Complex I inhibitor effect on the nigral and striatal release of dopamine in the presence and absence of nomifensine. Eur J Pharmacol. 1995. — V. 280. — P. 251−256.
- Sarre S., Yuan H., Jonkers N., Van Hemelrijck A., Ebinger G. and Michotte Y. In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats. J Neurochem. 2004. — V. 90. — P. 29−39.
- Scatton B., Dennis T., L’Heureux R, Monfort J. C., Duyckaerts C. and Javoy-Agid F. Degeneration of noradrenergic and serotonergic but not dopaminergicneurones in the lumbar spinal cord of parkinsonian patients. Brain Res. 1986. -V. 380.-P. 181−185.
- Schoenfeld R. and Uretsky N. Altered response to apomorphine in 6-hydroxydopamine-treated rats. Eur J Pharmacol. 1972. — V. 19. — P. 115−118.
- Schutz B., Schafer M. K., Eiden L. E. and Weihe E. Vesicular amine transporter expression and isoform selection in developing brain, peripheral nervous system and gut. Brain Res Dev Brain Res. 1998. — V. 106. — P. 181 204.
- Sedelis M., Schwarting R. K. and Huston J. P. Behavioral phenotyping of the MPTP mouse model of Parkinson’s disease. Behav Brain Res. 2001. — V. 125. -P. 109−125.
- Seeman P. Brain dopamine receptors. Pharmacol Rev. 1980. — V. 32. — P. 229 313.
- Sherer T. B., Kim J. H., Betarbet R. and Greenamyre J. T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol. 2003. — V. 179. — P. 9−16.
- Shih J. C., Chen K. and Ridd M. J. Monoamine oxidase: from genes to behavior. Annu RevNeurosci. 1999. — V. 22. — P. 197−217.
- Smith Y. and Villalba R. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains. Mov Disord. 2008. — V. 23 Suppl 3. — P. S534−547.
- Snyder G. L., Keller R. W., Jr. and Zigmond M. J. Dopamine efflux from striatal slices after intracerebral 6-hydroxy dopamine: evidence forcompensatory hyperactivity of residual terminals. J Pharmacol Exp Ther. -1990.-V. 253.-P. 867−876.
- Spector S., Sjoerdsma A. and Udenfriend S. Blockade of Endogenous Norepinephrine Synthesis by Alpha-Methyl-Tyrosine, an Inhibitor of Tyrosine Hydroxylase. J Pharmacol Exp Ther. 1965. — V. 147. — P. 86−95.
- Stachowiak M. K., Keller R. W., Jr., Strieker E. M. and Zigmond M. J. Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage. J Neurosci. 1987. — V. 7. — P. 1648−1654.
- Strome E. M. and Doudet D. J. Animal models of neurodegenerative disease: insights from in vivo imaging studies. Mol Imaging Biol. 2007. — V. 9. — P. 186−195.
- Svensson T. H. and Waldeck B. On the role of brain catecholamines in motor activity: experiments with inhibitors of synthesis and of monoamine oxidase. Psychopharmacologia. 1970. — V. 18. — P. 357−365.
- Takeda H., Inazu M. and Matsumiya T. Astroglial dopamine transport is mediated by norepinephrine transporter. Naunyn Schmiedebergs Arch Pharmacol. 2002. — V. 366. — P. 620−623.
- Tank A. W., Osterhout C. A. and Sterling C. R. Regulation of tyrosine hydroxylase activity by muscarinic agonists in rat adrenal medulla. J Pharmacol Exp Ther. 1998. — V. 286. — P. 848−854.
- Tepper J. M., Sun B. C., Martin L. P. and Creese I. Functional roles of dopamine D2 and D3 autoreceptors on nigrostriatal neurons analyzed by antisense knockdown in vivo. J Neurosci. 1997. — V. 17. — P. 2519−2530.
- Thornburg J. E. and Moore K. E. Supersensitivity to dopamine agonists following unilateral, 6-hydroxydopamine-induced striatal lesions in mice. J Pharmacol Exp Ther. 1975. — V. 192. — P. 42−49.
- Thorpe L. W., Westlund K. N., Kochersperger L. M., Abell C. W. and Denney R. M. Immunocytochemical localization of monoamine oxidases A and B in human peripheral tissues and brain. J Histochem Cytochem. 1987. — V. 35. — P. 23−32.
- Trojan S. and Pokorny J. Theoretical aspects of neuroplasticity. Physiol Res. -1999.-V. 48.-P. 87−97.
- Tzschentke T. M. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol. 2001. — V. 63. — P. 241−320.
- Udenfriend S., Zaltzman-Nirenberg P. and Nagatsu T. Inhibitors of purified beef adrenal tyrosine hydroxylase. Biochem Pharmacol. 1965. — V. 14. — P. 837−845.
- Uhl G. R., Walther D., Mash D., Faucheux B. and Javoy-Agid F. Dopamine transporter messenger RNA in Parkinson’s disease and control substantia nigra neurons. Ann Neurol. 1994. — V. 35. — P. 494−498.
- Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl. -1971.-V. 367.-P. 69−93.
- Uretsky N. J. and Iversen L. L. Effects of 6-hydroxydopamine on catecholamine containing neurones in the rat brain. J Neurochem. 1970. — V. 17.-P. 269−278.
- Vaughan R. A., Huff R. A., Uhl G. R. and Kuhar M. J. Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes. J Biol Chem. 1997. — V. 272. — P. 15 541−15 546.
- Walaas S. I., Aswad D. W. and Greengard P. A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions. Nature. 1983. — V. 301. — P. 69−71.
- Wickens J. Striatal dopamine in motor activation and reward-mediated learning: steps towards a unifying model. J Neural Transm Gen Sect. 1990. — V. 80. — P. 9−31.
- Widerlov E. Dose-dependent pharmacokinetics of alpha-methyl-p-tyrosine (alpha-MT) and comparison of catecholamine turnover rates after two doses of alpha-MT. J Neural Transm. 1979. — V. 44. — P. 145−158.
- Widerlov E. and Lewander T. Inhibition of the in vivo biosynthesis and changes of catecholamine levels in rat brain after alpha-methyl-p-tyrosine- time- and dose-response relationships. Naunyn Schmiedebergs Arch Pharmacol. 1978. -V. 304. — P. 111−123.
- Wirtshafter D., Stratford T. R. and Asin K. E. Evidence that serotonergic projections to the substantia nigra in the rat arise in the dorsal, but not the median, raphe nucleus. Neurosci Lett. 1987. — V. 77. — P. 261−266.
- Yavich L. Two simultaneously working storage pools of dopamine in mouse caudate and nucleus accumbens. Br J Pharmacol. 1996. — V. 119. — P. 869−876.
- Yoshida M. The GABAergic systems and the role of basal ganglia in motor control. Adv Biochem Psychopharmacol. 1981. — V. 30. — P. 37−52.
- Zhang W. Q., Tilson H. A., Nanry K. P., Hudson P. M., Hong J. S. and Stachowiak M. K. Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage. Brain Res. 1988. — V. 461. — P. 335 342.
- Zhu X. R., Maskri L., Herold C., Bader V., Stichel C. C., Gunturkun O. and Lubbert H. Non-motor behavioural impairments in parkin-deficient mice. Eur J Neurosci. 2007. — V. 26. — P. 1902−1911.
- Zigmond M. J. Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism. Neurobiol Dis. 1997. — V. 4. — P. 247−253.
- Zigmond M. J., Abercrombie E. D., Berger T. W., Grace A. A. and Strieker E. M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 1990. — V. 13. — P. 290−296.
- Zigmond M. J., Acheson A. L., Stachowiak M. K. and Strieker E. M. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch Neurol. 1984. — V. 41. — P. 856−861.
- Zigmond M. J., Berger T. W., Grace A. A. and Strieker E. M. Compensatory responses to nigrostriatal bundle injury. Studies with 6-hydroxydopamine in an animal model of parkinsonism. Mol Chem Neuropathol. 1989a. — V. 10. — P. 185−200.
- Zigmond M. J. and Strieker E. M. Supersensitivity after intraventricular 6-hydroxydopamine: relation to dopamine depletion. Experientia. 1980. — V. 36. — P. 436−438.
- Zigmond R. E., Schwarzschild M. A. and Rittenhouse A. R. Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation. Annu Rev Neurosci. 1989b. — V. 12. — P. 415−461.